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ABSTRACT 
Cancer is a global burden due to high incidence and mortality rates and is ranked the second 
most diagnosed disease amongst non-communicable diseases in South Africa. A high 
expression level of the 37kDa/67kDa laminin receptor (LRP/LR) is one characteristic of 
cancer cells. This receptor is implicated in the pathogenesis of cancer cells by supporting 
tumor angiogenesis, metastasis and especially for this study, the evasion of apoptosis. In the 
current study, the role of LRP/LR on cellular viability of breast MCF-7, MDA-MB 231 and 
WHCO1 oesophageal cancer cells was investigated. Western blot analysis revealed that total 
LRP expression levels of MCF-7, MDA-MB 231 and WHCO1 were significantly 
downregulated by targeting the mRNA of LRP using siRNA-LAMR1 by 100, 44% and 73%, 
respectively. This knockdown of LRP expression resulted in a significant decrease of 
viability in the breast and oesophageal cancer cells as determined by an MTT assay by 72%, 
52% and 45% in WHCO, MCF-7 and MDA-MB 231 cells, respectively. Moreover, the 
reduction in cellular viability was accompanied by a significant decrease in cell proliferation 
by 26%, 43% and 59% in MCF-7, WHCO1 and MDA-MB 231 cells, respectively.  The 
exposure of the phosphatidylserine protein on the surface of breast MCF-7, MDA-MB 231 
and oesophageal WHCO1 cancer cells as detected by the Annexin-V/7-AAD assay indicates 
that the reduction in cellular proliferation and viability is due to the induction of apoptosis 
which is elaborated by the  loss of membrane symmetry as well as observations of nuclear 
morphological changes in all cell lines post transfection with siRNA-LAMR1. This data 
indicates that LRP/LR is crucial for the maintenance of cellular viability of cancerous cells 
and our findings recommend siRNA technology as a novel alternative therapeutic approach 
for the treatment of metastatic cancer. 
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1. CHAPTER 1 – INTRODUCTION 
 
1.1. Cancer 
Cancer is a generic term referring to the growth of abnormal cells due to uncontrolled 
proliferation and lack of apoptosis that is caused by the accumulation of mutations that in 
turn compromise proper regulation of homeostasis[1]. Cancer arises when mutations 
observed in a single cell allow the cell to deregulate certain physiological processes i.e DNA 
repair checkpoints during the cell cycle; thus leading to transformation to a tumorigenic 
cell[1].  
This disease has gained huge interest from both the public and scientific community due to 
high prevalence and mortality rates worldwide (Figure 1, 2 and 3), affecting individuals of all 
races, ages, gender and class [2](GLOBOCAN 2012 and http://www.cancerresearchuk.org ).  
To date, cancer is the major cause of death worldwide, claiming about 8.2 million lives in 
2012 with 70% of these deaths observed in low- and middle-income countries (GLOBOCAN 
2012). Furthermore, current research studies propose that annual cancer cases will ascend 
from the 14 million observed in 2012 to 22 million by the year 2034(GLOBOCAN 2012). Of 
the 14.1 million new cases observed in 2012, about 50% of these new cases are accounted for 
by the five most common cancer types namely, lung, breast, liver, stomach and colorectal 
cancer (Figure 2) (Available from http://www.cancerresearchuk.org ). 
Of particular interest to this study, breast and oesophageal cancers were ranked the second 
and eighth most commonly diagnosed cancers in the world, respectively (Figure 2). 
Moreover, breast and oesophageal cancers were observed to be the fifth and sixth common 
causes of death amongst cancers worldwide, respectively [2] (Figure 3).  
The above statistics exemplify the urgency to discover alternative cancer treatments that will 
assist in eradicating this enduring cancer dilemma. 
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Figure 1: Worldwide cancer statistics in the year 2012. A chart indicating the new cancer and death cases 
worldwide accompanied by most commonly diagnosed and death-causing cancers. (Image adopted from 
GLOBOCAN 2012) 
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Figure 2: The 10 most commonly diagnosed cancers in the year 2012, worldwide. Image adopted from 
http://www.cancerresearchuk.org  
 
 
Figure 3: The 10 most common causes of cancer deaths in the year 2012 worldwide. Image adopted from 
http://www.canerresearchuk.org  
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1.1.1.  Cancer causes and prevention 
The transformation from a normal to a cancerous cell is not an isolated process; however, it is 
as a complex process governed by a series of evolutionary steps that may be due to internal 
(genetic instability, immune condition and epigenetic modifications) and external (radiation, 
infectious agents and tobacco) factors [3]. Numerous cancers have been identified as both 
preventable and non-preventable, with approximately 30% of cancers being preventable by 
incorporating lifestyle changes in order to minimize obesity, physical inactivity, smoking and 
exposure to certain external causative factors [4].  
Moreover, certain cancers are initiated or enhanced by infectious agents such as viruses 
including the Human Papilloma Virus (HPV) that causes cervical cancer [5, 6], Epstein-Barr 
Virus (EBV) that increases a person’s risk of being infected with nasopharyngeal cancer[7]. 
Kaposi sarcoma (KS) on the other hand is caused by infection with the Human herpesvirus 
(HHV-8) which also co-infects with the Human Immunodeficiency Virus (HIV) thus 
increasing a persons’ risk of developing KS when diagnosed with HIV, however the tumor 
may also develop in the presence of the HHV-8 or the Kaposi’s sarcoma-associated 
herpesvirus (KSHV), solely[8].  
1.1.2.  Cancer diagnosis and treatment 
Early diagnosis is crucial for the patients’ health as this allows for detection and eradication 
of the cancer whilst it is diminutive and has not metastasized to distant organs because 
treatment at this stage is limited and highly ineffective. Over the years, numerous diagnostic 
tools have been developed including, genetic tests, X-ray machines, magnetic resonance 
imaging (MRI) scans, ultrasound scans and nucleic markers[9].  
Furthermore, once diagnosed with this disease, there are numerous treatment options to assist 
in controlling or eradicating the tumor e.g. radiation, surgery, chemotherapy, immunotherapy 
and transplantation[9]. However, some of these techniques such as radiation tend to be non-
specific and  enhance cancer growth, thus studies focusing on understanding the mechanisms 
of cancer have paved way for the invention of advanced and more specific novel approaches 
including gene therapy, angiogenesis inhibitors, telomerase inhibitors and monoclonal 
antibody therapy[10].  
A majority of these recent treatment options target the alterations fundamental to tumor 
formation which have been described by Hanahan and Weinberg as the hallmarks of cancer 
(Figure 4).  
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Figure 4: The main hallmarks of cancer. The six main processes that facilitate transition from a normal to a 
cancerous cell. (Image adopted from[11]) 
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1.2. Cancer hallmarks 
 
1.2.1.  Sustaining proliferative signalling 
Normal cells cautiously regulate the release and production of growth signals that control 
entry into the cell cycle thus resulting in proper tissue homeostasis; however, cancerous cells 
deregulate these signals and are able to proliferate uncontrollably[1].    
Proliferation is well controlled in normal cells, with a distinct balance between growth-
promoting and anti-growth signals that control cellular division. Cancer cells have however 
acquired the ability to deregulate these signal by autocrine or paracrine signalling thus 
resulting in continuous cellular proliferation[12, 13]. They continue to proliferate even in the 
absence of nutrients or growth factors such the epidermal growth factor receptor (EGF-
R)[14]. These growth factors can be supplied by the cancer cells themselves or by normal 
cells that are stimulated by other cancer cells. Alternatively, somatic mutations such as PI3K, 
MAP-kinase, Ras or Myc may result in persistent activation of downstream proliferative 
pathways[15]. 
1.2.2.  Evading growth suppressors 
In addition to overexpression of growth-promoting signals, cancerous cells have also 
acquired the ability to evade anti-growth signals, mainly the tumor suppressor genes – 
retinoblastoma (RB) and P53[1].Tumor suppressors are crucial for normal growth as they 
regulate cell growth and proliferation in order to maintain proper tissue homeostasis and 
prevent tumor formation[1]. However, cancer cells must be able to inhibit the effects of these 
tumor suppressors in order to progress. The two main tumor suppressors are encoded by the 
retinoblastoma (Rb) and TP53 proteins, which either induce cellular proliferation, cell death 
or senescence depending on the cellular environment[11]. TP53 is a pro-apoptotic member 
that triggers apoptosis in unfavourable cellular conditions or excessive genome damage[16]. 
RB on the other hand decides whether a cell progresses through the cell cycle or remains in 
the Go phase until the conditions are favourable[17, 18]. However, cancer cells with 
mutations in these tumor suppressor genes lack the services of these key regulators of cell-
cycle progression and result in persistent abnormal cell proliferation and lack of apoptosis, 
which are the basis of tumor progression[1, 11]. 
1.2.3.  Inducing angiogenesis  
Similar to normal cells, cancerous cells need nutrients and oxygen in order to proliferate. 
Tumors aberrantly express vital growth factors and receptors – specifically, the angiogenic 
inducing factors such as upregulating vascular endothelial growth factor (VEGF) which 
facilitates blood vessel formation, providing conditions sufficient for rapid turnover due to a 
constant supply of blood, nutrients and oxygen[1, 19]. Moreover, tumors utilize the 
vasculature to eliminate metabolic waste and also as a route to migrate and metastasize to 
other organs[1, 19]. 
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1.2.4.  Activating invasion and metastasis 
Invasion and metastasis of epithelial cells is principally regulated by the epithelial-
mesenchymal transition (EMT). Tumorigenic cells selectively reduce their expression of cell-
cell adhesion molecules (CAMs), such as E-cadherin [20], alter integrin expression so as to 
express integrins suited to the composition of the extracellular matrix (ECM) at the distal 
secondary tumour site. Moreover, cancer cells may upregulate their expression of matrix 
degrading proteases (i.e. collagenases) vital for the disruption of the basal lamina that 
stimulates extravasation and initiation of migratory events[21].  
1.2.5. Enabling replicative immortality 
Numerous studies have illustrated that the presence of telomeres support proliferation due to 
the prevention of DNA damage by protecting the ends of chromosomes [22, 23]. In order to 
proliferate continuously, cancer cells have upregulated the expression of telomerase[24]. 
Limitless replicative potential is due to the enhanced telomerase activity observed in a vast 
number of cancerous cells[24]. Normal cells have low levels of telomerase, the enzyme 
required for the addition of telomere repeat segments that are crucial for protecting the ends 
of chromosomal DNA which prevents DNA damage[22]. The length of telomeric DNA tends 
to control the number of cell divisions that a cell can undergo before the ends of 
chromosomal DNA are damaged and compromise cell viability[22]. In turn, the enhanced 
telomerase activity allows cancer cells to divide uncontrollably as this corresponds to 
resistance to the occurrence of senescence and apoptosis by preventing progressive telomere 
shortening and resulting DNA damage[1]. Furthermore, the subunit of the telomerase 
enzyme, TERT plays a role in enhancing proliferation by resisting apoptosis due to its 
involvement in repairing DNA damage, however, further studies need to be carried out in 
order to elucidate the particular mechanism that this protein exerts this function[25]. 
1.2.6.  Resisting cell death  
Induction of cell death due to physiological stress or DNA damage is vital for the 
maintenance of a healthy cellular microenvironment and homeostasis [26, 27]. However, 
tumors have evolved to acquire a selection of tactics to circumvent apoptosis and, in turn, 
progressively grow and produce highly aggressive malignant tumors[1]. As mentioned 
previously, one common strategy is the loss or aberrant expression of P53, which allows the 
tumorigenic cells to by-pass the apoptosis-inducing circuitry and proliferate aberrantly to 
form enormous malignant tumor types[1, 28]. Tumors also avoid cell death by altering the 
expression of pro- and anti-apoptotic regulators of the death pathways to be dealt with later 
on, i.e. cancerous cells upregulate and downregulate the expression of anti- and pro-apoptotic 
Bcl-2 family members, respectively[1, 29]. The evasion of apoptosis has been observed to be 
a major hallmark of most if not all cancer types, thus targeting of mechanisms surrounding 
this hallmark is crucial for elucidation of possible therapeutic options of this disease[1].  
In addition to the above discussed hallmarks, there are two emerging cancer characteristics of 
tumors namely, reprogramming energy metabolism and avoiding immune destruction. The 
first entails the modification of the cellular energy metabolism inorder to sustain the 
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chronically proliferating tumor which requires supplementary nutrients and oxygen 
supply[11]. 
1.2.7. Reprogramming energy metabolism 
Apart from maintaining chronic proliferation and evading apoptosis cancer cells alter their 
environment by upregulating their energy metabolism in order to provide conditions that are 
suitable for cellular growth and division thus promote tumor progression[11]. One example is 
glycolytic fuelling which is the increased uptake of glucose which is involved in the 
activation of mutated tumor suppressor genes as well as oncogenes which feed into the basic 
hallmarks of tumorigenecity[11].   
1.2.8. Evading immune destruction 
The immune system has mechanisms of inhibiting the formation or progression of tumors 
such as DNA repair systems and cell cycle checkpoints. However, tumors have acquired the 
ability to bypass or avoid detection by the immune system[11]. Not much is currently known 
about these two hallmarks but the enabling characteristics governing these prcesses are 
tumor-promoting inflammation and the genome instability and mutation[11]. 
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1.3. Apoptosis 
This phenomenon was first described by Carl Vogt in 1842 and 100 years later termed 
“apoptosis” by John Kerr[30]. Apoptosis is a physiological well-ordered type of programmed 
cell death, in contrast to the catastrophic type of unprogrammed cell death – necrosis[31]. It 
is a crucial process from embryonic development all through to adulthood for immune 
regulation and achieving proper tissue homeostasis by regulating cell numbers and tissue 
size[32]. It is well-orchestrated and important  process throughout an persons’ lifespan , 
however, inappropriate execution of this process compromises physiological homoestasis and 
leads serious illnesses including AIDS[33], autoimmune diseases[34], liver diseases[34], 
neurodegenerative disorders[35] such as Alzheimer’s, Parkinson’s’ disease and crucial to this 
study cancer, which is as a result of minute apoptosis. Needless to say due to implications in 
such aggressive diseases, apoptosis has gained major interest from the scientific community 
aiming at formulating alternative therapeutic options regulating cell death mechanisms. 
The induction of apoptosis is stimulated by external (oxidative stress, growth factor 
withdrawal) and internal (DNA damage) stimuli resulting in physical changes such as 
chromatin condensation, cell shrinkage as well as biochemical alterations including DNA 
cleavage [30, 36, 37] (Figure 5). These features and cell membrane blebbing which triggers 
phosphotidylserine exposure are referred to as the hallmarks of apoptosis [36, 37]. As the cell 
progresses from early to late apoptosis the membrane integrity is lost and leads to packaging 
of the cellular contents in spheres known as apoptotic bodies, which are digested by 
macrophages; thus not posing harmful consequences to other cells or the cellular 
environment[37] (Figure 5). 
 
Figure 5: The main hallmarks of apoptosis. Apoptotic cells are characterized by physical and chemical 
changes. Once apoptosis is initiated, the cell shrinks and DNA fragmentation occurs followed by membrane 
blebbing that becomes convoluted forming apoptotic bodies. The apoptotic bodies package cellular contents 
which are digested by macrophages. (Image adopted from http://www.buzzle.com/articles/how-do-cells-
commit-suicide.html) 
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This process is executed by specific proteases known as caspases, both initiator i.e caspase-8, 
-10 and effector caspase-3, -6 and -7[38]. These enzyme precursors are synthesized inactive 
and are activated by proteolysis or transactivation upon contact with other caspases[38]. 
Although caspases are the executers of apoptosis the events preceding caspase activation 
differ and are dependent on the pathway activated between the two major pathways, the death 
receptor-mediated and mitochondrion-mediated cell death pathway [31, 32, 36]. These 
processes differ in certain respects including the stimuli required for initiation, and it is 
noteworthy to add that although the receptor-mediated pathway is rarely targeted for the 
study of oncogenic mutations a brief discussion on this pathway will also follow. 
1.3.1.  Extrinsic death receptor pathway 
This pathway is crucial for the regulation of the immune system and is triggered by the 
binding of the death receptors from the tumor necrosis factor (TNF) receptor superfamily 
composed of TNF-1, CD95 and the TNF-related apoptosis-inducing ligand (TRAIL)[39]. 
Binding of these receptors directs receptor trimerization where the adaptor Fas-associated 
death domain (FADD) proteins interact with Fas via the cytosolic domain [40-42]. This 
interaction induces the death effector domain (DED) of FADD to bind the DED of 
procaspase-8 thus forming the death inducing signalling complex (DISC) complex [43, 44]. 
In this complex, the procaspase-8 molecules are orientated in close proximity such that 
transactivation of these zymogens occurs and the active caspase-8 interacts with and activates 
one of the executioner caspases, caspase-3,-6 or -7 (Figure 6); resulting in the cleavage of key 
cellular substrates such as DNA molecules that are crucial for maintenance of  the cell’s 
viability thus leading to cellular destruction [43, 44]. 
1.3.2.  Intrinsic mitochondrial pathway 
This is the most targeted pathway of cell death as most cell death proceeds via this pathway 
and is triggered by both internal and external stimuli. Detection of the apoptotic signal 
triggers the release of cytochrome c along with Smac/DIABLO and AIF (Apoptosis Inducing 
Factor) from the mitochondrion upon activation of the pro-apoptotic members of the Bcl-2 
family (i.e. Bak, Bax, Bid & Bim) [45-47]. To date the precise mechanism regulating this 
event is still elusive, however, Ott et al. proposed that this release proceeds by a two-step 
mechanism initiated by the solubilisation of the cytochrome c molecules from the inner 
mitochondrial membrane by peroxidation of the anchoring-lipid, cardiolipin [48]. However, 
the solubilisation of these cytochrome c molecules is preceded by the permeabilization of the 
outer mitochondrial memebrane by Bax thus initiating the release cytochrome c into the 
cytosol [48]. Subsequently, seven cytochrome c molecules interact with seven apoptotic 
protease activating factor-1 (Apaf-1) and seven procaspase-9 molecules, forming the 
apoptosome [49]. Within the apoptosome the oligomerization of Apaf-1 by cytochrome c 
induces dimerization of the procaspase-9 molecules resulting in the release of active caspase-
9 molecules that in turn activate effector caspases such as caspase-3, leading to the cleavage 
of crucial cellular substrates to effect the occurrence of apoptosis[49] (Figure 6). 
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Indeed for apoptosis to occur the above mentioned events are crucial, however, induction of 
apoptosis is not solely controlled by pro-apoptotic signals but an integration between both 
pro- and anti-apoptotic signalling and the progression of this system is often more complex. 
 
 
Figure 6: The two main pathways of apoptosis in mammalian cells. The death receptor pathway detects an 
external stimuli (i.e oxidative stress) leading to the interaction of FADD proteins with Fas by a process 
known as receptor trimerization. This complex induces the DED of FADD to bind to the DED of 
procaspase-8 molecules thus forming the DISC complex. This complex is crucial for the transactivation of 
procaspase-8 molecules to active caspase-8 molecules that activate the effector caspases thus inducing 
apoptosis. The intrinsic pathway is activated by both internal and external stimuli that trigger the release 
of cytochrome C that is required to interact with Apaf-1 and procaspase-9 molecules forming the 
apoptosome. Within the apoptososme, oligemirization of Apaf-1 by cytochrome C leads to dimerization of 
procaspase-9 molecules, releasing active caspase-9 molecules that activate effector caspases and induce 
apoptosis. (Image adopted from[50]). 
 
Moreover, researchers have described as many as eleven cell death pathways in mammals; 
however, there are only two more types of cell death pathways that have been clearly defined, 
namely autophagic cell death and necrosis[51]. All cells can undergo either of the three cell 
death pathways and inorder to produce appropriate potential therapeutics targeting cell death 
one has to be able to clearly identify the form of cell death between the three[51]. Therefore, 
a brief discussion on the characteristics to distinguish between the three cell death types and 
the distinct hallmarks of apoptosis follows. 
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1.4. Autophagic cell death 
Autophagic cell death also referred to as type II cell death is stimulated by signals such as 
nutrient starvation, differentiation and environmental stress[52]. This form of cell death is 
crucial for the recycling of long-lived proteins and components of organelles by the 
lysosomes for the maintenance of energy and protein synthesis[52]. Upon detection of the 
signal, double-membrane bound structures assemble to form autophagosomes, vacuole-
shaped structures that contain cytosolic material[52]. These structures fuse with lysosomes 
thus leading to the degradation of the encapsulated cytosolic material[52]. This is a 
physiologically critical process; however, excessive autophagy has pathological implications, 
causing neurodegenerative diseases, liver diseases and cancer [53, 54]. 
 
1.5. Necrosis 
Necrosis is an energy-independent form of cell death that is considered to result in prominent 
energy depletion, activation of non-apoptotic proteases and formation of reaction oxygen 
species.  [55]. This results in cytoplasmic swelling, dilation of prominent organelles 
(mitochondria, Golgi apparatus, and endoplasmic reticulum), rupture of the cell membrane as 
well as condensation of chromatin material[56]. Continuous swelling stimulates the cell to 
burst, resulting in the leakage of the cytoplasmic contents which cause an inflammatory 
response[56].  
 
1.6. Hallmarks of apoptosis 
 
1.6.1.  Caspase activation 
Caspases are a family of proteases that are produced in an inactive enzyme form known as 
zymogens with an N terminal prodomain, followed by a large and small subunit [38]. These 
enzymes undergo caspase maturation by cleavage on the carboxyl side of aspartate residues 
achieved by other caspases or the cytotoxic T lymphocyte serine protease granzyme B[38].   
The prodomains of these zymogens differ in length, ranging from 23 amino acids to 219 
amino acids. Initiator caspases such as caspase-8, -9 and -10 generally have long prodomains 
and effector caspases 3, 6 and 7 have short prodomains[38]. 
Upon activation, caspases cleave particular substrates thus resulting in their activation or 
inactivation. The cleavage of fundamental components of the cytoskeleton, nucleus and 
proteins of major signalling pathways results in numerous morphological changes associated 
with apoptosis as will be discussed shortly. 
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1.6.2.  Membrane alterations 
Cell membrane blebbing is one major characteristic of apoptosis induction, resulting in the 
exposure of phospholipid phosphatidylserine (PS) to the outer membrane[57]. This lipid 
bilayer-forming lipid is generally situated in the inner cell membrane in live cells; however, 
upon induction of apoptosis it is translocated to the outer cellular membrane [57, 58]. This 
caspase-dependent mechanism is crucial for recognition of apoptotic cells as well as serving 
as a signal to phagocytes that require binding to PS receptors, thus leading to prompt 
engulfment of apoptotic cells without provoking  an inflammatory response[59] (Figure 5). 
1.6.3.  DNA fragmentantion 
DNA cleavage is another crucial feature as it assists in the elimination of DNA that codes for 
autoantibodies that can cause hyperactivity of the immune system thus resulting in the 
demolishment of healthy tissue[60]. This process is initiated by the caspase-mediated 
cleavage of the inhibitor of caspase-activated DNase (ICAD), resulting in free, active CAD 
that produces multiple DNA double-stranded breaks of 180 base pairs in size [61, 62]. This is 
not a strictly specific process as the active CAD may degrade various parts of the entire 
genome leading to a loss of essential genes thus resulting in the induction of cell death[61]. 
1.6.4.  Mitochondrial changes 
In contrast to membrane alterations and DNA fragmentation, mitochondrial modifications 
precede apoptosis because it is crucial for the release of cytochrome c molecules that are 
required for the formation of the apoptosome in the intrinsic mitochondrial pathway[63]. It is 
proposed that the pro-apoptotic molecules of the Bcl-2 family such as Bax interacts with the 
mitochondrion and induce mitochondrial outer membrane permeabilization (MOMP) which 
is accompanied by  the solubilisation of cytochrome c molecules from the anchoring lipid, 
cardiolipin thus leading to cytochrome c release and formation of the apoptosome in the 
intrinsic pathway[63]. 
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1.7. The cell cycle 
Proper functioning of an organism requires adequate completion of the cell cycle in all the 
cells in the body. This is a tightly regulated process that is crucial for cellular growth by 
mediating duplication[64], replication and transfer of genetic information in the form of 
chromosomes into daughter cells[65]. The coordination of these complex events is achieved 
by the cyclin dependent kinases (CDKs) by driving the cell through the five stages of the cell 
cycle, namely, gap 0 (Go), gap 1 (G1), gap 2 (G2), mitosis (M phase) and the S phase that is 
responsible for DNA synthesis[65] (Figure 7).  
During the Go phase the cell remains quiescent or senescent meaning it is currently inactive 
in the cycle, either temporarily or permanently but is metabolically active[65]. Extracellular 
signals such as growth factors, mitogens or nutrient availability stimulates quiescent cells to 
enter G1 and proceed to the S phase for DNA synthesis[65]. Precise DNA replication allows 
for procession to the G2 phase where cells expand in size and proteins required for the M 
phase are synthesized[65]. These proteins are required for the duplication of the mitotic 
spindles, separation and migration of sister chromatids to opposite poles of the cell prior to 
cytokinesis, resulting in two identical daughter cells[65]. 
There are cell cycle checkpoints (G1-S and G2-M) that are responsible for ensuring the order 
of events in the cell cycle and monitoring crucial events such as DNA replication[65]. 
Stringent regulation of these events is crucial as accumulation of mutations cause loss of 
genome integrity and leads to unstable genomes that could evolve normal cells to cancerous 
cells[65]. These mutations afford cells the ability to proliferate independently of growth 
signals and reduced sensitivity to death signals[65]. The checkpoints assist in the correct 
regulation of the cell cycle and should an error be encountered progression through the cell 
cycle is halted until it has been fixed, however, if it is a severe error cell death is immediately 
induced[66]. 
The above mentioned processes and the million events that occur in cells daily do not occur 
in an isolated system, however, there is an integration of communication amongst cells and 
their environment, the extra-cellular matrix (ECM). 
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Figure 7: The cell cycle. The cell cycle comprises of five stages; G0 – the cell remains quiescent but 
metabolically active, S – the cell’s DNA replicates, G1 – cells enter this phase in response to nutrient 
availability, G2 – the cell grows in size, M – mitotic spindles are formed and cell division occurs following sister 
chromatid segregation. (Image adopted from://www.bdbiosciences.com/research/apoptosis/analysis/index.jsp) 
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1.8. Extracellular matrix (ECM) 
The ECM is a complex matrix that functions to provide signals that regulate cell behaviour, 
navigational signals for migrating cells, contact with neighbouring cells and supply of 
nutrients and growth factors via specialized receptor molecules[67]. It is crucial for cell 
survival in both plants and animals, with the cell wall representative of the ECM in plants 
whereas in animals it appears in two forms, the basement membrane and the stromal 
matrix[67].  
This matrix is made up of a mixture of diverse molecular components that are essential for 
regulation of these cellular processes and varies in composition and volume between tissues 
of an organism as well as with developmental age. It is mainly composed of proteoglycans 
and glycoproteins such as, collagens, elastin, fibronectins, matrix metalloproteinases 
(MMPs)[68] (Figure 8) and of particular interest to this study, the laminins. 
 
 
Figure 8: The extracellular matrix. The ECM is made up of the basement membrane and stromal matrix 
which consists of molecular components that are crucial for cellular processes. Proteoglycans and glycoproteins 
such as collagens, elastin, fibronectin and MMPs are the main components. (Image adopted from 
http://wiki.pingry.org/u/ap-biology/images/5/52/Image122.gif) 
 
1.8.1. Laminins 
Laminins are major ECM glycoproteins that are made up of three α, β and γ chains that are 
stabilised by disulphide bonds to form a cross shape[69] (Figure 11). These 5α, 3β and 3γ are 
able to assemble into numerous different heterotrimers and the resulting trimers are named 
according to their chain composistion such as α1β1γ1 is referred to as laminin-111 and 
α2β1γ2 known as laminin-212. To date, there are 17 laminin isoforms that are 
known[69].These heterotrimeric proteins have various binding sites for components of the 
ECM such as collagen, proteoglycans, integrins and with other laminin molecules thus 
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forming sheets in the basal lamina that are crucial for cell differentiation, migration, adhesion 
and survival[69].  
One prominent binding site is the cell-surface receptor binding domain that allows laminins 
to bind to the 37-kDa/67-kDa laminin receptor precursor/high affinty laminin receptor 
(LRP/LR), thus regulating crucial cellular events, such as adhesion and signal transduction. 
 
 
 
  
 
Figure 9: Structure of laminin-1. The cross of laminin is made up of three α, β and γ chains stabilised by 
disulphide bonds. It has binding sits for numerous ECM molecules including collagen IV, entactin, heparin and 
cell surface receptors. (Image adopted from http://themeekgroup.com/Christian/laminin.htm) 
 
 
 
18 
 
1.9. The 37-kDa/67-kDa laminin receptor precursor/laminin receptor (LRP/LR) 
This laminin receptor was first isolated in 1983 from murine melanoma, human breast 
carcinoma and normal muscle cells by purification from the cell membrane using laminin-
sepaharose affinity chromatography [70-72]. This receptor was found to have a molecular 
mass of 67-kDa encoding for a 295 amino acid long protein with a 37-kDa molecular weight 
thus leading to the conclusion that the 37-kDa gene product is the precursor of the 67-kDa 
high affinity laminin receptor (LR), hence referred to as the laminin receptor precursor (LRP) 
[73]. Since the discovery of this relationship there has been numerous studies aimed at 
understanding how this occurs, however, the exact mechanism has not been elucidated except 
for proposals that this may be through homodimerization that requires post-translational 
modifications [74, 75]. However, a study by Landwoski illustrated that inhibition of fatty acid 
synthesis prevents formation of the 67-kDa LR thus implying that acylation of LR by fatty 
acids (palmitate, stearate and oleate) is perhaps crucial for maturation from the 37-kDa 
LRP[74] , therefore the term LRP/LR will be used to refer to the 37kDa/67kDa laminin 
receptor throught this manuscript .  
This type II transmembrane protein (Figure 10) localises on the cell surface, nucleus[76-78] 
and cytosol[79, 80] acting as a receptor for numerous molecules, assisting in the maintenance 
of nucleic structures by binding to histones and regulation of translational processes[81], 
respectively. As the name suggests, its’ primary binding ligand is laminin-1 which it binds 
with high affinity and specificity via three regions in the C-terminal domain, namely residues 
161-180[82], most C-terminal 53 residues[83] and residues 205-229[74] (Figure 12).  
This LRP/LR-laminin-1 interaction is implicated in the regulation of crucial cellular 
processes such as cell adhesion, migration, proliferation and protease activity[84]. In addition 
to regulating these physiological processes by binding laminin-1, LRP/LR also acts as a 
receptor for extracellular matrix components i.e elastin, carbohydrates and cellular prion 
proteins[85]. Moreover, the LRP/LR has been implicated in numerous pathological processes 
by facilitating the internalization of bacteria[85], viruses[86-88] and infectious prion 
proteins[85]. Of particular importance to this study, is the overexpression of this receptor on a 
number of cancer types, which is correlated to cancer progression. 
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Figure 10: Structure of the 37-kDa/67-kDa laminin receptor precursor/ laminin receptor (LRP/LR). 
LRP/LR is a 295 aa long transmembrane protein. It is a type II membrane protein with the N-terminus and C-
terminus exposed to the cytoplasmic side and extracellular space, respectively. It binds PrP, heparin, IgG 
antibodies and laminin. (Image adopted from[89]) 
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1.10. Relation of the laminin receptor and cancer 
High levels of LRP/LR expression were first noted in numerous cancer types, such as 
breast[90], lung[91], cervical[92], ovarian[93], colon[94], gastric[95], heptocellular[96] and 
prostate[97] cancer cells, when compared to corresponding normal cells. To date there is no 
data implicating particular stimuli responsible for this differential expression, however,  
overexpression of this receptor has been observed to augment tumor aggressiveness by 
affording cancer cells the enhanced ability to metastasize[98], induce angiogenesis[99] and 
evade cell death[99].  
1.10.1. LRP/LR-laminin-1 interaction and metastasis 
The first possible role of LRP/LR in cancer was noted by Rao in 1983 suggesting that the 
67kDa laminin receptor plays a role in the interaction between the metastasizing cancer cell 
and the basement membrane[72]. During metastasis, adherence of the invasive cancer cells 
triggers degradation of the basement membrane, allowing the cancerous cell to invade the 
surrounding stroma and migrate through the bloodstream to a distant organ to form a 
secondary tumor[1, 100]. The two key steps of this process is the adhesion and invasion of 
the basement membrane, which are events mediated by the LRP/LR-laminin-1 
interaction(Figure 11)[100]. 
Moreover, the LRP/LR-laminin-1 interaction is significantly enhanced in tumors that express 
the 67kDa laminin receptor at high levels thus promoting the malignancy of that tumor[101, 
102]. Although the mechanism has not been clearly elucidated, it is suggested that upon 
adherence to the basement membrane via the LRP/LR-laminin-1 interaction, LRP/LR triggers 
the secretion of Type IV collagenase, a protease that mediates degradation of the main 
component of the basement membrane, Type IV collgen thus facilitating invasion[89]. In 
vitro metastatic studies have illustrated that an anti-LRP/LR specific antibody IgG1-iS18 
significantly impedes adhesion and invasion of important cancer types worldwide, i.e 
prostate, colon, cervical, lung, breast, oesophageal and liver cancer, by interfering with the 
LRP/LR-laminin-1 interaction [101-103]. 
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Figure 11: LRP/LR-laminin-1 interaction and metastatic cancer. The enhanced LRP/LR-laminin-1 
interaction in metastatic cells allows cells to adhere to the basement membrane, leading to the hydrolysis of type 
IV collagen by type IV collagenase. This allows cells to invade surrounding tissue and migrate to a secondary 
site to form a tumor. However, incubation of colon SW480 cells with IgG1-iS18 anti-LRP/LR specific antibody 
significantly impeded invasion of these cancer cells. (Image adopted from [102]) 
 
1.10.2. The role of LRP/LR in tumor angiogenesis 
Angiogenesis known as the formation of blood vessels is imperative for wound healing, 
embryonic development, vascular remodelling and tissue repair by supplying cells around the 
body with sufficient oxygen and nutrients[104]. This process is controlled precisely in 
healthy individuals, however, in individuals with cancer it is deregulated in order to form 
additional tubular structures that will assist in facilitating metastasis by providing the tumors 
with routes to migrate through and initiate secondary metastasis in a distant organ[105]. 
Furthermore, angiogenesis also supports the viability of cancer cells by providing them with 
oxygen and nutrients which are crucial for cellular growth[105]. The formation of these 
tubular structures requires cell-ECM interactions and since LRP/LR binds the ECM protein 
laminin-1, resulting in proteolytic activation, a fundamental process in angiogenesis, this 
gave rise to speculations that LRP/LR may be involved in tumor angiogenesis[105]. Indeed, a 
study conducted in our laboratory confirmed that LRP/LR is involved in the angiogenic 
process following the observation of a significant decrease of tube formation in HUVECs 
(human umbilical vein endothelial cells) post treatment with anti-LRP/LR specific antibody 
W3(Figure 12)[106]. 
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Figure 12: Illustration of the effect of anti-LRP/LR specific antibody W3 on angiogenic tube formation. 
(A) Administration of anti-LRP/LR antibody W3 to HUVE cells that had established tubular structures on 
Matrigel™, inhibited further degradation of the basement membrane, a prerequisite for tube formation. This 
halted the development of additional tubular structures, moreover, W3 antibody bound to existing tubes and 
blocked the LRP/LR-laminin-1 interaction, hence resulting in (B) the reversal of tube formation and cells were 
consequently observed as single cells on the Matrigel™ (Image adopted from [106]) 
 
1.10.3. LRP/LR and cellular viability 
LRP/LR is conserved across all species and ribosomal studies in yeast have illustrated that 
the this receptor plays a crucial role in cellular viability by processing the 20S ribosomal 
RNA to 18S and in turn leading to the maturation of 80S monosome and 40S ribosomal unit 
that regulate cell survival[107]. The ribosomal functions of LRP/LR in mammalians have not 
been clearly elucidated; however, it has been observed that LRP/LR upregulates signalling 
pathways that are crucial for cell survival[76]. Moreover, it is hypothesized that LRP/LR 
associates with chromatin and the nuclear envelope during interphase, facilitating 
chromosomal stability that sequentially maintains cell viability[76]. It is believed that the 
LRP/LR attains this by binding chromatin and the nuclear envelope with the cell migration, 
proliferation and cell survival promoting growth factor Medkine[108]. Furthermore, 
Scheiman et al conducted a cell viability study in human HT1080 fibrosarcoma cells 
demonstrating that the LR requires the C-terminus for effective cellular viability 
maintainance[80]. 
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1.10.4. LRP/LR and the evasion of apoptosis 
LRP/LR has been implicated in cancer progression by inhibiting apoptosis. It is expected 
though because as stated above that LRP/LR plays a role in maintainance of cellular viability 
and since this receptor is expressed in high levels in several cancerous cells, its pro-cell 
survival role is augmented in these cancer types. siRNA constructs targeting the expression of 
37kDa LRP mRNA in Hepb3 liver and HeLa cervical cancer cells stimulated the induction of 
apoptosis, clearly indicating the role of LRP/LR in blocking apoptosis[109]. Furthermore, a 
study conducted in our laboratory using siRNA LAMR1 in HeLa cervical and A549 lung 
cancer cells resulted in the reduction of LRP/LR expression that sequentially stimulated the 
induction of apoptosis by activating caspase-3, the effector caspase of apoptosis[110]. These 
results evidently indicate that LRP/LR is a crucial potential target for the treatment of cancers 
that reveal high expression levels of this receptor.  
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1.11. Applications of small interfering ribonucleic acid (siRNA) technology 
siRNAs are 9 – 21 nucleotide long dsRNA sequences that are produced to stimulate 
degradation of target complimentary sequences present in cellular mRNA[111]. siRNAs 
achieve this by either suppressing transcription (known as transcriptional gene silencing) or 
activating sequence specific RNA degradation (referred to as posttranscriptional gene 
silencing (PTGS)) or the RNAi pathway[111]. The RNAi pathway has been observed in most 
eukaryotic organisms such as parasites[112], flies[113], protozoa[114], humans[115] as well 
as plants. This mechanism utilizes the dsRNA molecules as the inducers that cleave inducer 
molecules thus resulting in the degradation of the target mRNA molecules[111].  
The main components of the PTGS/RNAi pathway are the Dicer and RNA-Induced 
Signalling Complex (RISC) that are involved in the initiation of the PTGS/RNAi pathway 
and degradation of the target mRNA[116], respectively (Figure 13). 
1.11.1. Dicer 
The Dicer is a nuclease with four main domains: a dsRNA binding domain, PAZ domain, an 
amino terminal helicase domain and dual RNase III motifs [117-119]. Subsequent to binding 
of the dsRNA molecules to Dicer, the Dicer digests dsRNA forming small 22 bp sized siRNA 
molecules which are further digested by the RNase III nucleases into 12 – 15 bp[111, 120]. 
The digestion of dsRNA to siRNA occurs at two catalytic centres of the dimeric RNase III 
enzyme [120]. The RNase III enzyme folds on either sides of the dsRNA substrate, producing 
four catalytic sites with the two terminal sites containing maximum homology with the 
RNAse III catalytic sequences, whilst the other sites lose activity due to partial 
homology[121]. This enables the Dicer to process double the size of dsRNA molecules when 
compared to other RNase III enzymes[121]. 
1.11.2. RNA-Induced Signalling Complex 
RISC is the nuclease activity accountable for the degradation of target mRNA in a sequence 
specific manner. This complex is made up of the Argonaute (Ago), Tudor-Staphylococcus 
nuclease (Tudor-SN) and fragile X-related (FXR) domain proteins[116]. 
This mechanism of RNA interference using the PTGS/RNAi pathway has not been clearly 
elucidated but has been summarised into three fundamental steps: 
This pathway is initiated by the binding of the RNA III nuclease Dicer to dsRNA, facilitating 
cleavage of the dsRNA into 21 – 25 bp siRNA fragments[111]. The second step entails the 
incorporation of siRNAs into the complex, RISC by the dsRNA-binding protein R2D2[111], 
which stimulates enzymatic activation of the RISC zymogens in the presence of ATP to 
mediate the unwinding of the double stranded siRNA (Figure 13)[111]. Subsequently, the 
least stable siRNA strand of the two is discarded and only the most stable siRNA strand is 
left bound to the complex, hence this is the effector step[121]. Step 3 facilitates gene 
silencing. Whilst the single stranded siRNA is bound to the complex, the activated RISC 
cleaves the target mRNA endonucleolytically at the region complimentary to the 
siRNA[122], which is usually ten nucleotides upstream of the nucleotide paired with the 5’ 
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end of the siRNA[123] (Figure 13). This cleavage step has been observed to operate 
independently of ATP[124]; however, the release of the cleaved products occurs more 
efficiently in the presence of ATP[113]. 
 
 
 
Figure 13: RNA interference mechanism. Dicer cleaves the dsRNAs into siRNAs. The siRNAs are 
incorporated into the RISC complex and bind to their complimentary mRNA sequences in the cells. Once 
bound, the target mRNA is degraded and remains non-functional. (Image adopted from Society of Toxicologic 
Pathology, 35 (3) 2007) 
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Numerous studies have focused on the application of RNA interference as a therapeutic tool 
for treatment of diseases that are caused by the altered expression of certain genes such as 
viral infections[125], genetic disorders[126], autoimmune diseases as well as cancer[127].  
It is proposed that these diseases may be treated by modifying the activity of these genes by 
RNAi based therapeutics. Furthermore, it is relatively effortless introducing synthetic siRNAs 
in vitro and effective gene silencing has been observed, however, delivery of these molecules 
in vivo still remains challenging. This is still the case because non-specific targeting of 
normal cells occurs thus compromising the health of the individual. Nonetheless, RNAi based 
therapeutics are currently being developed for numerous viruses including, respiratory 
synytial viruses (RSV), hepatisis B virus (HBV) and the human immunodeficiency virus 
(HIV)[125].  
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1.12. Rationale, research question, aim, objectives 
 
1.12.1. Rationale 
LRP/LR has been found to be expressed in high levels in numerous cancer cells when 
compared to their corresponding normal cells. The high expression of this receptor affords 
cancer cells with the ability to enhance metastasis, angiogenesis and cellular proliferation, 
which are all prominent hallmarks of cancer. Moreover, the knockdown of LRP/LR has been 
observed to reduce viability of certain cancer cells thus indicating the fundamental role of 
LRP/LR in cellular viability. The high incidence and mortality rates observed worldwide with 
respect to cancer indicate the urgency of alternative therapeutic options and the role of 
LRP/LR in cancer progression is undeniable. Therefore targeting of this receptor may 
possibly pave a way for the elucidation of  promising therapeutic tools that can be utilised for 
the treatment of cancer. 
1.12.2. Research question 
Will downregulation of LRP/LR expression using specific siRNAs or the interference of the 
LRP/LR-laminin-1 interaction using anti-LRP/LR antibody IgG1-iS18 reduce the viability of 
breast (MCF-7 & MDA-MB 231) and oesophageal (WHCO1) cancer cells, and if so, which 
mechanism of cell death is responsible for the observed effects? 
1.12.3. Aim 
To investigate whether downregulation of the LRP/LR using siRNA technology affects the 
cellular viability of breast (MCF-7 & MDA-MB 231) and oesophageal (WHCO1) cancer 
cells.  
1.12.4. Objectives 
 
 Determination of the effect of anti-LRP/LR specific antibody IgG1-iS18 on the 
cellular viability of MCF-7, MDA-MB 231 and WHCO1 cells since this antibody 
significantly impeded the adhesion and invasion, key steps of metastasis of these 
cancer cell lines by interfering with the LRP/LR-laminin-1 interaction 
 
 Downregulation of LRP expression in MCF-7, MDA-MB 231 and WHCO1 cells by 
transfection of siRNA-LAMR1 
 
 Analysis of the effect of siRNA-mediated downregulation of LRP/LR on the cellular 
viability of MCF-7, MDA-MB 231 and WHCO1 cells using an MTT assay 
 
 Determination of the effect of siRNA-mediated downregulation of LRP/LR on the 
proliferative state of MCF-7, MDA-MB 231 and WHCO1 cells using a BrdU assay 
 
 Identification of the type of cell death activated following siRNA-mediated 
downregulation of LRP/LR expression if an effect on cell viability is observed using 
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 Annexin-FITC and 7-AAD assay – to observe the exposure of 
phosphatidylserine (PS) during membrane blebbing, a hallmark of 
programmed cell death apoptosis 
 Immunofluorescence microscopy – visualisation of nuclear morphological 
changes associated with activation of apoptosis 
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2. CHAPTER 2 – MATERIALS AND METHODS 
 
2.1. Cell lines and cell culture conditions 
 
2.1.1. Cell lines 
The following cell lines were used in this study 
 Human breast adenocarcinoma cell line (MCF-7 ATCC®HTB-22) – An adherent 
non-metastatic human breast cancer cell line isolated from a 69-year-old Caucasian 
woman in 1970. 
 Human breast adenocarcinoma cell line (MDA-MB 231 ATCC®HTB-26) – An 
adherent metastatic epithelial breast cancer cell line derived from a 51-year-old 
Caucasian female. 
 Human oesophageal carcinoma cells (WHCO1) – this metastatic cell line is not 
commercially available; it was propagated in vitro from tumor biopsy of a patient 
with this type of oesophageal cancer[128].  
2.1.2.  Cell culture conditions 
Human breast adenocarcinoma MCF-7 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) high glucose (4.5 g/l) (Invitrogen Gibco®). MDA-MB 231 breast cancer 
cells were cultured in DMEM/Hams F12 (1:1) and WHCO1 oesophageal cancer cells were 
cultured in DMEM/Hams F12 (3:1), respectively. All media were supplemented with heat 
inactivated 10% (v/v) fetal calf serum (Sigma) and 1% (10 000 U/ml) penicillin/streptomycin 
(Separations) at 37
0
C and 5% CO2. 
 
2.2. Analysis of the interference of the LRP/LR-laminin-1 interaction on the cellular 
viability of cancer cells using the anti-LRP/LR specific antibody IgG1-iS18 
 
4 x 10
5
 MCF-7, 3.5 x 10
5
 MDA-MB 231 and 3 x 10
4
 WHCO1 cells were seeded in the wells 
of a 24-well plate and incubated with 50 mg/ml of IgG1-iS18 after 24 h. Post 17 h incubation 
with the anti-LRP/LR specific antibody, anti-CAT antibody (negative control), 8 mM PCA 
(positive control – known to decrease cell viability by inducing apoptosis); cells were stained 
with 0.1% (v/v) crystal violet and the absorbance of the colorimetric solution was measured 
at 570 nm using an ELISA reader. 
 
 
 
 
 
 
 
30 
 
2.3. Downregulation of LRP expression 
 
2.3.1.  Transfection of MCF-7, MDA-MB 231 and WHCO1 cells with siRNA-
LAMR1 and siRNA-scr 
 
24 h before transfection, MCF-7, MDA-MB 231 and WHCO1 cells were seeded in the wells 
of a 6-well plate. 5 µl of 20 µM siRNA-LAMR1 (5’-TTGGTTCCCATCGTAACTAA-3’) 
and 5 µl of 20 µM siRNA-scr (negative control) (Inqaba Biotec) were each resuspended  in 
195 µl of serum-free media (appendix). Concurrently, 10 µl of the DharmaFECT® 
transfection reagent 1 was resuspended in 190 µl of serum-free media; both solutions were 
incubated at room temperature (RT) for 5 min. The siRNA solutions and transfection reagent 
solutions were mixed gently and incubated for 20 min at RT. Media from the plated wells 
was removed and 400 µl of the siRNA-reagent solution was added to each well and media 
was topped up to 2 000 µl with antibiotic-free media. Cells were allowed to grow for 72 h in 
a humidified incubator at 37
o
C with 5% CO2 and 95% air. 
 
2.3.2.  Whole cell lystate preparation 
72 h post transfection media was aspirated out; cells were rinsed with PBS (appendix) and 
incubated in 250 µL of lysis buffer (appendix) for 2 min. Cells were detached using a sterile 
cell scraper and the resulting solution was incubated at 4
o
C for 15 min prior to centrifugation 
at 14 000 rpm for 2 min to mediate protein extraction. Resulting lysates were stored at 4
o
C 
until required. 
2.3.3.  Protein quantification 
The amount of protein present in the whole cell lysate was quantified using the Biocichoninic 
acid (BCA) assay (Sigma-Aldrich). This colorimetric assay is based on the reduction of 
copper ions (Cu
2+
) to Cu
+
 by peptide bonds of proteins. The reduction results in a violet 
complex of Cu
+
 and biocinchoninic acid, thus indicating the amount of protein present 
relative to the intensity of the resulting solution that can be measured spectrophotometrically 
at 562 nm. 
Bovine serum albumin (BSA) standards (Separations) (0, 0.2, 0.4, 0.6, 0.8 and 1 mg/mL) 
were prepared and 25 µL of each standard was aliqouted to a 96-well plate in triplicate. 
Whole cell lysates obtained from the transfected cells (Section 2.3.2) were diluted (1:5) and 
25 µL each lysate was pipetted into the wells of the 96-well plate in triplicate. Subsequently, 
BCA and copper (II) sulfate were mixed in a 1:50 ratio and 200 µL of this solution was added 
to each well prior to a 30 min incubation at 37
o
C. Absorbance of the resulting solutions was 
measured using an ELISA reader at 562 nm and the concentration of each protein lysate 
sample was extrapolated from the standard curve obtained.  
Protein lysates were diluted with dH2O to a 1 mg/ml solution in a 1:2 ratio with 2X sample 
loading dye (appendix) and stored at 4
o
C until required. 
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2.3.4.  Sodium dodecyl sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
SDS-PAGE was employed in order to separate the proteins in the cell lysate prior to detection 
of total LRP levels by Western blotting. Proteins were separated according to their molecular 
weight based on the observation that size is inversely proportional to mobility. However, 
proteins have different overall charges thus the protein lysates were denatured by heat in the 
presence of the anionic detergent SDS that confers an overall negative charge on all proteins 
thus allowing separation based on size only. This permits the proteins to migrate through the 
polyacrylamide gel that sieves the proteins by impeding the migration of larger proteins 
relative to smaller ones based on the amount of acrylamide used, down to the anode. In this 
study a 12% (v/v) polyacrylamide gel was used to in order to detect the protein of interest 
LRP/LR. 
Following heat denaturation of the protein lysates at 95
o
C for 5 min in loading buffer 
(appendix), 10 µl of the protein samples were loaded into gel slots along the pre-stained 
molecular weight marker (Thermoscientific) and ran using 1X SDS running buffer 
(appendix) at 200V for approximately 30 min. 
2.3.5.  Western blotting and immunodetection 
The resulting gel was electro-blotted onto a 0.45µm polyvinylidene fluoride (PVDF) 
membrane at 450 mV for 45 min in order to transfer the protein pattern obtained using 
transfer buffer (appendix) and filter paper soaked in transfer buffer. Subsequent to transfer, 
the blotted PVDF membrane was incubated in blocking buffer (appendix) for 1 hour at RT. 
The membrane was then incubated with primary antibody (anti-LRP/LR specific antibody 
IgG1-iS18) (Affirmed Therapeutics) and for β-actin detection the Anti-β-Actin-Peroxidase 
antibody (Sigma-Aldrich) was used; with both antibodies resuspended in PBS. The 
membranes were then incubated for an hour at RT followed by three 10 min PBS-Tween 
washes prior to detection of the primary LRP antibody by incubation of the membrane with 
the secondary antibody (anti-human IgG-HRP (horse-radish peroxidase) conjugated) (Sigma-
Aldrich) resuspended in blocking buffer (appendix) for 1 h. 
Membranes for both LRP/LR and β-actin detection were washed with PBS-Tween for 10 min 
three times and these proteins were detected using the Super WestPico Chemilumniscent 
substrates in a 1:1 ratio. The resulting protein bands were exposed to an X-ray film then 
developed and fixed onto the film using developer and fixer (both from Sigma-Aldrich), 
respectively. 
2.3.6.  Densitometry analysis 
 
Quantification of LRP/LR expression levels was completed by densitometry analysis. An 
image of the X-ray film with the proteins of interest was captured using the GS-800 
Calibrated Densitometer and densitometric analysis done using the Quantity One – 4.5.2 
software. Intensities of the bands were calculated and the calibration curve was obtained from 
which the area known as Integrated Optical Density (IOD) was calculated and used to 
compare the LRP/LR expression levels in MCF-7, MDA-MB 231 and WHCO1 cells post 
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transfection with siRNA-LAMR1 relative to the non-transfected protein lysates of these cell 
lines. The loading control (β-actin) was not included in densitometry analysis. 
 
2.4. Examination of the downregulation of LRP/LR expression on the viability of 
cancerous cells 
The following assays were employed on the various tumorigenic cell lines in order to 
investigate the effect of LRP/LR siRNA-mediated downregulation on cellular viability. 
2.4.1.  Mitochondrial tetrazolium salt (MTT) assay 
This assay is based on the cleavage of the yellow MTT salts by the mitochondrial succinate 
dehydrogenase enzyme of viable cells into water insoluble purple formazan crystals. The 
amount of crystals produced provided an estimate of viable cells that are able to produce the 
succinate dehydrogenase enzyme to carry out this cleavage. 
Cells seeded in a 24-well plate were transfected and incubated in a humidified incubator at 
37
o
C and 5% CO2 for 72 h. Cells treated with 8 mM PCA and siRNA-scr were used as a 
positive and negative, respectively. 500 µl of a 1 mg/ml solution of MTT dissolved in PBS 
was added to each well prior to a 2 h incubation in the humidified incubator. Media was 
aspirated, formazan crystals were dissolved in 200 µL of DMSO and absorbance was 
measured at 570 nm using an ELISA plate reader. 
2.4.2.  Bromodeoxyuridine (BrdU) proliferation assay 
This immunoassay utilizes the incorporation of bromodeoxyuridine (BrdU) incorporation into 
new DNA molecules of actively dividing cells as an evaluation of proliferating cells. BrdU is 
a thymidine analogue as a result during DNA synthesis BrdU will be incorporated into the 
new DNA molecules as a substitute for thymidine. Upon labeling non-transfected, siRNA-
LAMR1-transfected, siRNA-scr-transfected (negative control) and 8 mM PCA-treated 
(positive control) cells with BrdU, an anti-BrdU antibody was used to detect incorporated 
BrdU and a horseradish peroxidase-conjugated secondary antibody was used in order to bind 
to the detector antibody, resulting in catalysis of the conversion of the fluorogenic substrate 
to a blue product that can be measured spectrophotometrically with an ELISA reader at 540 
nm. 
MCF-7, MDA-MB 231 and WHCO1 cells were seeded in a 96-well plate and transfected as 
previously described; with cells treated with 8 mM PCA and siRNA-scr used as a positive 
and negative control, respectively. Post 72 h incubation in a humidified incubator set at 37
o
C 
and 5% CO2, 20 µL BrdU (Merck) working stock solution diluted in fresh culture media 
(1:2000) was pipetted to each well and incubated for 2 h in the tissue culture incubator. 
Contents were removed; cells were fixed and denatured with 200 µL of Fixative/Denaturing 
solution for 30 min at room temperature. This was to enable antibody binding to the BrdU 
label, thus cells were incubated with the detector anti-BrdU antibody for 1 h at room 
temperature, followed by a 30 min incubation with the secondary peroxidase anti-mouse IgG-
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HRP conjugate antibody. 100 µL of Substrate solution was added to each well and the 
horseradish peroxidase catalysed the conversion of this fluorogenic substrate to a blue 
product and the reaction was halted with 100 µL of Stop solution after 15 min and 
absorbance was measured. 
2.4.3.  Annexin V-FITC/ 7AAD assay 
This assay analyzes the loss of asymmetry in cell membrane phospholipids due to altered 
hydrophobicity and charge on the membrane surface. In healthy cells, phosphatidylserine 
(PS) is localized on the inner membrane, however, in apoptotic cells, PS translocates to the 
outer membrane thus indicating membrane alteration upon induction of apoptosis. In this 
assay, Annexin-V, a high affinity phospholipid-binding protein binds to PS exposed on the 
cell surface of apoptotic cells thus indicating cells that are undergoing apoptosis in the 
population. Moreover, the DNA-binding 7-AAD dye stains late apoptotic cells positively but 
is excluded from early apoptotic cells thus allowing for distinction between early and late 
apoptotic cells. 
MCF-7, MDA-MB 231 and WHCO1 cells were seeded and transfected in a 24-well plate as 
done previously. Post 72 h incubation, cells were detached with trypsin/EDTA 
(Thermoscientific) and cell suspensions were rinsed with ice-cold PBS prior to centrifugation 
at 500 x g for 5 min. The resulting pellets were resuspended in ice-cold 1X Binding Buffer at 
a density of 7 x 10
6
 cells/mL and all subsequent steps were performed at 4
o
C. 100 µL of the 
four cell suspensions (untreated, PCA-treated (positive control), siRNA-scr-treated (negative 
control) and siRNA-LAMR1-treated) were stained with 10 µL of 2.5 µg/mL concentrated 
Annexin V-FITC and 20µl the 0.005% 7-AAD viability dye (Beckman Coulter) in a total 
volume of 100 µL for 15 min in the dark. Furthermore, 100 µL of ice-cold 1X Binding buffer 
was added and samples were analyzed immediately using the BD Accuri flow cytometer 
software. Annexin V-FITC staining was analysed using the FL1 laser whilst 7-AAD staining 
was analysed using the FL3 laser and the following controls were used to set compensation 
and quadrants; unstained cells, Annexin-V-FITC stained cells, 7-AAD stained cells, Annexin 
V-FITC and 7-AAD stained cells as well as 8 mM PCA treated cells stained with both 
Annexin V and 7-AAD. 
2.4.4.  Immunofluorescence microscopy 
MCF-7, MDA-MB 231 and WHCO1 cells were seeded onto coverslips and after 24 h were 
transfected with siRNA-LAMR1, siRNA-scr (negative control) and 8mM PCA (positive 
control). 72 h post transfection, media was aspirated and cells were fixed with 4% PFA for 15 
min and washed with cold PBS. Nuclei was stained with 0.5 µL of  10 mg/ml Hoescht 33342 
stain resuspended in 95 µL PBS for 5 to 10 min at RT, subsequent to mounting onto a slide 
using Gelmount (Sigma Aldrich) for 1 h at RT in the dark. Slides were stored at 4
o
C until 
visualization using the blue laser, under the 63X objective and the Zen 2011 software of the 
Zeiss LSM 710 3-Channel  Confocal microscope. 
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3. CHAPTER 3 – RESULTS 
 
LRP/LR has numerous cellular localisations (the cytosol, cell surface, perinuclear 
compartment and the nucleus) and the cell surface and total LRP/LR levels were determined 
in MCF-7, MDA-MB 231 and WHCO1 cells in a previous study in our laboratory. Indeed, 
the aforementioned cell lines expressed high total and cell surface LRP/LR levels as 
determined by western blotting and flow cytometry[101], respectively. Additionally, 
Khumalo et al illustrated that high expression of this receptor aggravated the metastatic 
potential of these cells lines due to the enhancement of the LRP/LR-laminin-1 
interaction[101]. Furthermore, incubation of these cell lines with the anti-LRP/LR specific 
antibody IgG1-iS18 resulted in the inhibition of adhesion and invasion, the key steps of 
metastasis in the invasive MDA-MB 231 breast and WHCO1 oesophageal cancer cell 
lines[101].  
 
This observation instigated the question whether IgG1-iS18 might also affect the viability of 
these cancer cell lines by interfering with the LRP/LR-laminin-1 interaction. 
 
3.1. Examination of the interference of the LRP/LR-laminin-1 interaction on the 
cellular viability of breast and oesophageal cancer cells 
 
Incubation of MCF-7, MDA-MB 231 and WHCO1 cells with IgG1-iS18 for 17 h had no 
effect on the viability when compared to both untreated (set to 100%) and anti-CAT-treated 
cells (Figure 14). However, incubation of these cells with 8 mM PCA) resulted in significant 
reduction of viability across all cell lines. 
 
 
Figure 14: The effect of the LRP/LR-laminin-1 interaction on the cellular viability of WHCO1, MCF-7 and MDA-
MB 231 cells post incubation with anti-LRP/LR specific antibody IgG1-iS18. The viability of WHCO1, MCF-7 and 
MDA-MB 231 cells was analysed 17 h post incubation with 50 μg/μL of IgG1-iS18, anti-CAT and 8 mM PCA. 
IgG1-iS18 had no effect on the cellular viability of all cell lines when compared to the untreated cells set to 
100%. 8 mM PCA and anti-CAT antibody were used as positive and negative controls, respectively. 
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Having observed no effect of the anti-LRP/LR antibody on the cellular viability of these cell 
lines, introduction of siRNA into MCF-7, MDA-MB 231 and WHCO1 cells was performed 
in order to potentially reduce the expression of LRP and determine whether reduction of LRP 
expression significantly influences cell viability and cell proliferation. 
 
 
3.2. Downregulation of LRP expression 
 
The level of LRP expression in MCF-7, MDA-MB 231 and WHCO1 cells post transfection 
with siRNA-LAMR1 (siRNA targeting mRNA of the 37kDa LRP) was determined by 
western blotting and densitometry analysis (Section 2.3). 
 
Densitometric analysis of the western blots signals revealed that siRNA-LAMR1 transfected 
MCF-7, MDA-MB 231 and WHCO1 cells displayed a significant 100% (p < 0.01), 44% (p < 
0.001) and 73% (p < 0.05) reduction in LRP expression, respectively, when compared to the 
non-transfected cells which have been set to 100% and using β-actin as a loading control 
(Figure 15). Transfection of all cell lines with siRNA-scr (negative control) displayed non-
significant reduction in LRP expression, compared to the non-transfected cell lysates.  
 
 
 
Figure 15: LRP expression in WHCO1, MDA-MB 231 and MCF-7 cells post-transfection with siRNA-
LMAR1. The expression levels of the 37kDa LRP in WHCO1, MDA-MB 231 and MCF-7 cells was 
investigated post-transfection with siRNA-LAMR1 by western blotting. Densitometric analysis of the western 
blot signals revealed significant (p<0.05 differences in LRP expression in a) WHCO1, b) MDA-MB 231 and c) 
MCF-7 cells, respectively (compared to non-transfetced cells). 
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3.3. Determination of the effect of downregulation of LRP expression on cellular 
viability 
 
Significant downregulation of LRP expression resulted in significant reduction of the cellular 
viability of MCF-7, MDA-MB 231 and WHCO1 cells (Figure 16). The cellular viability was 
analysed using an MTT assay which was performed on cells incubated with 8mM PCA and 
transfected with siRNA-scr and siRNA-LAMR1 (Section 2.4.1).  
 
MCF-7, MDA-MB 231 and WHCO1 cells treated with siRNA-LAMR1 displayed significant 
52% (p < 0.001), 45% (p < 0.05) and 72% (p < 0.001) reduction in cellular viability, 
respectively (Figure 16). siRNA-scr treated MCF-7, MDA-MB 231 and WHCO1 cells 
exhibited no decrease in cell viability whilst 8mM PCA treated cells of these corresponding 
cell lines displayed significant reduction in cellular viability as expected (Figure 16).  
 
 
 
Figure 16: The effect of siRNA-mediated downregulation of LRP expression on the cellular viability of 
WHCO1, MCF-7 and MDA-MB 231 cells. The viability of WHCO1, MCF-7 and MDA-MB 231 cells was 
analysed 72 h post-transfection using an MTT assay. siRNA-LAMR1 treated WHCO1, MCF-7 and MDA-MB 
231 cells revealed significant 72%, 52% and 45% reduction in cellular viability, respectively, compared to 
untreated cells set to 100%. 8mM PCA and siRNA-scr were used as positive and negative controls, respectively. 
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3.4. Determination of the effect of LRP downregulation on proliferation of breast 
and oesophageal cancer cells 
Having observed a significant decrease in the viability of these breast and oesophageal cancer 
cell lines post downregulation of LRP, a BrdU assay was employed in order to analyse the 
effects of downregulation of this receptor on cellular proliferation as the two processes are 
intimately linked (Section 2.4.2). 
The BrdU assay revealed that the cellular proliferation of MCF-7, MDA-MB 231 and WHCO1 cells 
treated with siRNA-LAMR1 was significantly reduced by approximately 26% (p < 0.05), 59% (p < 
0.01) and 45% (p < 0.01), respectively (compared to non-transfected cells) (Figure 17) 
 
Figure 17: The effect of siRNA-mediated downregulation of LRP expression on cellular proliferation. The 
proliferation of WHCO1, MCF-7 and MDA-MB 231 cells was analysed 72 h post-transfection with siRNA-
LAMR1, siRNA-scr and incubation with 8mM PCA. siRNA-LAMR1 treated WHCO1, MCF-7 and MDA-MB 
231 cells exhibited a significant 45%, 26% and 59% reduction in cellular proliferation, respectively (compared 
to untreated cells set to 100%) (8mM PCA was used as a positive control).  
 
3.5. Assessment of siRNA-mediated downregulation of LRP expression on cell 
membrane integrity 
The cell membrane integrity of MCF-7, MDA-MB 231 and WHCO1 cells was assessed 72 h 
post transfection with siRNA-LAMR1, siRNA-scr and treatment with 8mM PCA. The 
aforementioned cell lines were stained with Annexin V-FITC and the 7-AAD viability dye 
(Section 2.4.3). 
A majority of siRNA-LAMR1 treated MCF-7, MDA-MB 231 and WHCO1 cells were 
located on the lower right and upper right quadrants when analysed using the flow cytometer 
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(Figure 18). The lower right quadrant is indicative of early apoptotic cells that are positive for 
Annexin-V binding and negative for the 7-AAD dye, whereas the upper right quadrant shows 
late apoptotic cells that are positive for both Annexin-V and 7-AAD binding. Furthermore, 
the siRNA-scr treated and untreated MCF-7, MDA-MB 231 and WHCO1 cells were located 
on the lower left quadrant that illustrates viable cells that exclude the 7-AAD dye and are 
negative for Annexin-V binding (Figure 18). The shift of the siRNA-LAMR1 treated cells to 
the lower left and upper left quadrants indicates that these cells are undergoing early, late 
apoptosis and necrosis as indicated by the varying FITC and 7-AAD signals (Figure 18). 
Moreover, the 8mM PCA treated cells exhibited similar results across all cell lines which is 
anticipated because PCA is a known apoptosis inducer. 
 
Figure 18: The effect of siRNA-mediated downregulation of LRP expression on cell membrane integrity. 
72 h post-transfection, MCF-7, MDA-MB 231 and WHCO1 cells were stained with Annexin-V FITC and 7-
AAD then analysed by flow cytometry. siRNA-LAMR1 treated MCF-7, MDA-MB 231 and WHCO1 cells 
revealed high FITC and 7-AAD signals indicative of cells undergoing early and late apoptosis, compared to 
untreated and siRNA-scr treated cells (8mM PCA was used as a positive control). 
 
3.6. Examination of the effect of siRNA-mediated downregulation of LRP expression 
on nuclear morphology 
Nuclear morphology of MCF-7, MDA-MB 231 and WHCO1 cells was assessed 72 h post 
transfection with siRNA-LAMR1, siRNA-scr and incubation with 8mM PCA by staining 
with the fluorescent nuclear dye Hoescht 33342 (Section 2.4.4).  
These cells were viewed using an immunofluorescence microscope, siRNA-LAMR1 treated 
MCF-7, MDA-MB 231 and WHCO1 cells as well as the 8mM PCA-treated corresponding 
43% Late 
apoptosis 
45.6% 
Necrosis 
57% Late 
apoptosis 
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cells exhibited constricted nuclei that have lost their original nuclear morphology when 
compared to the untreated and siRNA-scr treated cells that exhibit normal nuclei (Figure 19). 
This is shown by the crescent shaped nuclei (white arrows pointing siRNA-LAMR1 treated 
MDA-MB 231 cells) due to the collapse of chromatin[129] (Figure 19). Furthermore, 
progressive condensation of the chromatin (siRNA-LAMR1 treated WHCO1 micrograph) 
resulted in the shrinkage of the entire nucleus as indicated by the white arrows pointing to the 
siRNA-LAMR1 treated MCF-7 cells (Figure 19).  Additionally, post 72 h incubation with the 
transfections and 8mM PCA, the cell number was inconsistent between the untreated and 
PCA treated cells suggesting that the toxicity of PCA does indeed impact on cell viability 
hence there was a reduction in cell numbers observed between the micrographs.  
 
 
 
Figure 19: The effect of siRNA-mediated downregulation of LRP expression on nuclear morphology. 72 h 
post-transfection, MCF-7, MDA-MB 231 and WHCO1 cells were stained with Hoescht 33324 and viewed by 
immunofluorescence microscopy. siRNA-LAMR1 treated MCF-7, MDA-MB 231 and WHCO1 cells displayed 
condensed nuclei and decreased nuclear integrity (indicated by white arrows), compared to untreated and 
siRNA-scr treated cells (8mM PCA used as a positive control) 
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4. CHAPTER 4 - DISCUSSION 
The affiliation between the LRP/LR and cancer aggressiveness has been extensively 
investigated over the years. This huge interest was instigated by the observation of 
overexpression of this receptor on numerous cancer cells when compared to their normal 
counterparts [90, 91, 94, 130-132]. The overexpression of LRP/LR has been shown to afford 
cancer cells with the ability to metastasize to distant organs[98, 99], enhance 
angiogenesis[132] and evade apoptosis[99], which are cancer-supporting processes. 
LRP/LR’s implication in these hallmarks of cancer is anticipated because the LRP/LR has 
numerous cellular localisations (perinuclear compartment [77, 80, 133], cell surface [79], 
nucleus [77, 133] and the cytosol[80, 134]) interacting with various proteins, including ones 
that are involved in the above mentioned processes. LRP/LR is therefore considered a 
valuable prognostic marker for analyses of the severity of tumors[135] and additional roles of 
this receptor in cancer may be suggested as more investigations are carried out.  
4.1. Examination of the interference of the LRP/LR-laminin-1 interaction on the 
cellular viability of breast and oesophageal cancer cells 
A previous study in our laboratory by Khumalo et al revealed that breast MCF-7, MDA-MB 
231 and oesophageal WHCO1 cancer cells express high cell surface levels as well as 
significantly high total LRP levels[101]. High expression of this receptor was shown to 
enhance adhesion and invasion of the metastatic MDA-MB 231 and WHCO1 cancer cell 
lines[101]. However, incubation of these cell lines with anti-LRP/LR specific antibody IgG1-
iS18 significantly impeded adhesion and invasion in both cell lines, thus indicating that the 
LRP/LR-laminin-1 interaction is pivotal for the process of metastasis[101]. IgG antibodies 
are known to bind to LRP/LR via the antibody binding domain from amino acid 272 to 280 
and it is hypothesized that the antibody  alters the binding affinity of laminin-1 by steric 
hinderance, by occupying the laminin binding site on LRP/LR directly or influencing the 
MAPK signalling pathway through laminin and these still need to be examined[136]. 
The high expression of LRP/LR observed in these cells lines as well as successful inhibition 
of metastasis using IgG1-iS18 led to the investigation of whether this antibody will impact on 
the viability of these cancer cells. In this study, incubation of the cancer cell lines MCF-7, 
MDA-MB 231 and WHCO1 with the antibody IgG1-iS18 had no effect on the viability of 
these cancer cells. This result suggests that the LRP/LR-laminin-1 interaction targeted by 
IgG1-iS18 is not responsible or involved in the maintenance of cellular viability but mediates 
adhesion and invasion of cancer cells thus enhancing metastasis. It is crucial to note that the 
cells were not seeded onto laminin-1 coated plates, however, these cells do express laminin-
1[137-139], and hence it is presumed that the LRP/LR-laminin-1 interaction occurs in this 
system. The secretion of this ECM component by these cells as well as other tumor and 
stromal cells has been shown to be enhanced by paracrine and autocrine mechanisms by 
radiolabelling and immunoprecipitation assays [140]. 
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4.2. LRP silencing 
Since the incubation of breast MCF-7, MDA-MB 231 and oesophageal WHCO1 cancer cells 
with the anti-LRP/LR specific IgG1-iS18 antibody had no effect on the viability of these cell 
lines, the role of LRP/LR in cellular viability was analysed post-downregulation of this 
receptor. Knockdown of LRP was conducted by RNA interference technology. 
siRNA-LAMR1, a siRNA directed against the mRNA of LRP was utilised (purchased from 
Thermoscientific). This siRNA targets the open reading frame of the human LRP gene and 
was introduced to MCF-7, MDA-MB 231 and WHCO1 cancer cells using Transfection 
Reagent 1. LRP expression was significantly reduced by 43% in MDA-MB 231, 73% in 
WHCO1 and 100% in MCF-7 cells, as detected by western blot signals and densitometric 
analysis. These results indicate the high efficacy of siRNA-LAMR1 as well as the 
transfection method employed. 
It is crucial to note that siRNA-LAMR1 targets the mRNA of the 37-kDa LRP and not that of 
the 67-kDa LR. However, studies have shown that the 37-kDa form is the precursor of the 
67-kDa form [73]; therefore  a reduction in LRP expression correlates to a reduction in LR 
expression. Furthermore, the 67-kDa form cannot be targeted directly because it is not a 
direct product of translation or transcription but produced as result of post-translational 
modification of the 37-kDa LRP form that is still elusive[75, 141]. It is suggested that 
conversion of the 37-kDa LRP form to the 67-kDa LR form requires acylation at Ser 2 by 
fatty acids (palmitate, stearate and oleate)[141].  
Moreover, only the 37-kDa form is detected by western blotting and this might be due to the 
low concentrations of the 67-kDa form in cytoplasmic extractions [79]. Although it is clear 
that the control siRNA-scr had no effect on the expression of LRP/LR and that siRNA-
LAMR1 is specific relative to the control it is crucial to note that siRNA-LAMR1 may have 
had off-target effects, however it is certain that this siRNA targeted the C-terminus of 
LRP/LR as this is the region responsible for the maintenance of cellular viability as observed 
below. Furthermore, the effects of another LRP/LR-specific siRNA targeting a different 
region on the receptor in order to observe whether similar effects will occur thus controlling 
for and assessing the specificity of siRNA-LAMR1. 
4.3. Cellular viability 
The effect of downregulation of LRP expression on the viability of breast MCF-7, MDA-MB 
231 and oesophageal WHCO1 cancer cells was examined. Downregulation of LRP 
expression was accompanied by a significant reduction in the viability of MCF-7, MDA-MB 
231 and WHCO1 cancer cells by 43%, 46% and 72%, respectively, thus indicating the crucial 
role of LRP/LR on cellular viability. MCF-7, MDA-MB 231 and WHCO1 cells transfected 
with siRNA-scr exhibited no differences on cellular viability (compared to non-transfected 
cells), further indicating the prominent effect of siRNA-LAMR1.  
Evasion of apoptosis is one prominent characteristic of cancer cells and it is evident that high 
levels of LRP expression afford cancer cells the ability to maintain cellular viability and in 
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turn enhance propagation of the tumour. LRP/LR is indeed a pathologically significant 
protein in this disease and it has been hypothesized that LRP/LR maintains cellular viability 
by retaining chromosomal stability in cells by binding to the growth factor Midkine 
(MK)[108]. MK with a molecular weight of 13 000 is a heparin-binding growth factor that is 
involved in modulating numerous functions such as cell migration, proliferation, fibrinolysis 
and angiogenesis[142]. In normal individuals the serum level of MK is less than 0.6 nm/ml, 
however, in cancer patients with breast, bladder, lung, stomach, prostate and oesophageal 
cancer the levels of this growth factor are elevated[142]. By binding to Medkine, LRP/LR is 
thought to associate with the nuclear envelope and chromatin material, connecting the latter 
to the former thus retaining chromosomal stability [108]. Furthermore, studies have 
illustrated that MK cause cells to upregulate the expression levels of PKB, mTor and Bad 
which are components crucial for maintenance of cell survival and inhibits apoptosis by 
inhibiting the expression of caspase-3, the effector caspase[142]. Elevated blood levels of 
MK have been observed in the cell lines of this study as well, breast MCF-7, MDA-MB 231 
and oesophageal WHCO1 cancer cells, and also regarded as a diagnostically useful marker as 
MK levels correlate with disease stage and prognosis in these cancers[142]. This proposed 
mechanism partly explains the results observed when the various cancer cell lines were 
incubated with IgG1-iS18 which targets the LRP/LR-laminin-1 interaction. This mechanism 
is dependent on the expression of LRP/LR and not the LRP/LR-laminin-1 interaction, hence, 
IgG1-iS18 had no effect on the cellular viability of the above mentioned cancer cell lines. 
4.4. Cellular proliferation 
Cellular proliferation was assessed in order to elucidate whether the observed reduced cell 
viability of MCF-7, MDA-MB 231 and WHCO1 cells could be due to the inhibition of 
cellular division. Proliferation was similarly reduced following downregulation of LRP 
expression by 26%, 45% and 59% in MCF-7, WHCO1 and MDA-MB 231 cells, respectively. 
This is comprehensible because LRP is physiologically involved in cellular proliferation and 
also binds to MKe, which is a growth factor known to mediate cell proliferation as well as 
migration and survival [108]. Therefore, reduced expression of LRP/LR may possibly result 
in suggests a lowered LRP/LR-MK interaction thus resulting in hampered cell proliferation 
and survival.   
Furthermore, as a ribosomal protein LRP/LR has been shown to be crucial for protein 
translation by associating with the 40S ribosomal subunit, which is a process required for the 
progression of the cell through the G1 to S phase hence a reduction in cell proliferation is 
observed upon downregulation of this receptor [143]. Additionally, LRP/LR expression may 
promote the translation of proteins required for cell-cycle progression, whilst reduced 
expression of this receptor may induce translation of cell cycle arrest proteins. This may 
indicate that LRP/LR’s ribosomal functions are crucial for the regulation of cell proliferation, 
however, to ascertain this a cell cycle study may be conducted. The cell cycle RT
2
 Profiler 
PCR Array in order to investigate whether cell cell cycle-related gene expression is altered 
between siRNA- LAMR1-transfected and non-transfected cells focusing on cyclins, p21 and 
survivin expression levels 
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4.5. Apoptosis 
Apoptotic assays were conducted in order to elucidate whether the reduction in cellular 
viability of MCF-7, MDA-MB 231 and WHCO1 cells is due to this form of programmed cell 
death. Indeed apoptosis was responsible for the observed decrease in cellular viability as 
illustrated by the nuclear morphological changes following downregulation of LRP/LR using 
siRNA-LAMR1.  
The loss of nuclear integrity is no surprise because LRP/LR localises in the perinuclear 
compartment [77, 133, 143] and the nucleus [77, 133]. It is believed that LRP/LR binds to 
histones thus assisting in the maintenance of nuclear structures[81], therefore, loss or reduced 
expression of this receptor leads to instability of nuclear structures which triggers induction 
of apoptosis which is illustrated by Hoescht which binds to dsDNA thus allowing for 
visualisation of DNA that may be compromised which is indicative of apoptosis induction.  
Apoptosis occurrence was further exhibited by the Annexin-V FITC/7-AAD assay carried on 
the above mentioned cell lines (Section 2.4.3). Annexin-V is an intracellular protein that 
binds to PS, which is located in the intracellular leaflet of the plasma membrane of viable 
cells[144]. In viable, intact cells the Annexin-V cannot bind to PS as it is excluded, however, 
during apoptosis the cell membrane integrity is compromised and the phospholipids lose their 
asymmetry and translocate to the outer leaflet of the membrane[145]. Exposure allows the 
Annexin-V to bind in the presence of calcium thus stain cells undergoing apoptosis[145]. 
This is observed in Figure 18 where the untreated and siRNA-scr treated cells are stained 
negative for Annexin-V binding (lower right quadrant) whereas the 8mM PCA and siRNA-
LAMR1 treated cells are stained positive for Annexin-V binding (lower and upper right 
quadrants). This shift illustrates that as the expression of the LR is downregulated in MCF-7, 
MDA-MB 231 and WHCO1 cells, cell membrane alterations (membrane blebbing) occur as 
the cells experience apoptosis. It is crucial to note that the Annexin-V is conjugated to FITC 
for detection purposes and studies have shown that addition of this fluorochrome does not 
impact on the phospholipid binding properties of Annexin hence it is appropriate for analysis 
of cell membrane asymmetry in cells[145]. 
Additionally, Annexin-V binding cannot distinguish between early and late apoptotic 
cells[145], hence the 7-AAD viability dye was utilised as well. Similarly to Annexin-V, 7-
AAD does not stain viable cells as it cannot be incorporated to into intact cells. This dye 
undergoes a spectral shift upon interaction with DNA emitting at 647 nm which is 
appropriate for flow cytometric analysis[146]. Following membrane alterations, 7-AAD 
enters the cell and passes through to the nucleus to stain DNA [147, 148]. Early apoptotic 
cells that are only experiencing proteolytic digestion exclude 7-AAD dye thus this dye only 
stains cells that have progressed through the apoptotic pathway and have experienced 
membrane alterations. The early and late apoptotic cell populations are observed in the 
siRNA-LAMR1 treated MCF-7, MDA-MB 231 and WHCO1 cells (lower and upper right 
quadrants, respectively) as displayed in the micrographs.  
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Furthermore, it was observed that a majority of siRNA-LAMR1 treated MCF-7 and WHCO1 
cells experience late apoptosis with 43% and 57%, respectively (Figure 18). However, only 
26% of siRNA-LAMR1 treated cells were undergoing late apoptosis with a majority (45%) 
experiencing necrosis (upper left quadrant). There is no particular reason for this observation; 
however, one can speculate that the MDA-MB 231 breast cancer cell line may be more 
susceptible to LRP/LR downregulation as this receptor plays a more prominent role in this 
cell line; which may be attributed to the fact that  MDA-MB 231 is a triple negative breast 
cancer (TNBC) cell line, not expressing progesterone (PR), estrogen (ER) and the Human 
Epidermal Growth Factor Receptor 2 (HER 2) [149, 150]. Thus propagation of this cancer is 
independent of the presence of these receptors, therefore the high expression of LRP/LR may 
be crucial for survival, growth and progression when compared to other cell lines, and hence 
this cell line is more susceptible to LRP knockdown and experienced necrotic cell death. 
Similarly, this data may suggest that LRP/LR predominantly induces necrosis rather than late 
apoptosis in this cell line. Furthermore, the proliferation and cell viability studies, BrdU and 
MTT assays indicate significant hampering of these two crucial processes following 
knockdown of LRP/LR expression by about 59% and 45%, respectively, which further 
supports the observation of a majority of the MDA-MB 231 breast cancer cell line 
experiencing necrosis. However, it is also important to note that all experiments were carried 
out 72 h post transfection with siRNA-LAMR1 and analysis after shorter incubation times 
could yield different results. Moreover, further experiments may be conducted in order to 
elucidate whether the observed effects are specific or more pronounced in TNBC ER+ or 
TNBC PR+ cell lines. A breast cancer-focused investigation starting with determination of 
expression profiles of genes in a collection of breast cancer cells by RNA isolation and 
quantitative real-time PCR which will allow for characterisation of the breast cancer cell lines 
into either TNBC ER+ or TNBC PR+. Known TNBC PR+ breast cancer cell lines (i.e T47D) 
and TNBC ER+ (MDA-MB-361) [151]will then be transfected with siRNA-LAMR1 for 
knockdown of LRP/LR expression and similar assays (i.e viability MTT, proliferation BrdU, 
apoptosis assays) will be conducted with these cells and appropriate conclusions will be made 
from the observations.  
To further demonstrate apoptosis in the above cell lines, the nuclear morphology was 
investigated by Hoescht staining. Disruptions in the nuclear morphology of siRNA-LAMR1 
treated breast MCF-7, MDA-MB 231 and oesophageal WHCO1 cancer cells were clearly 
evident. Nuclear morphological changes and membrane alterations are representative of 
apoptosis thus indicating the crucial role of the laminin receptor in cancer progression by 
inhibiting the induction of apoptosis. Moreover, LRP/LR may be supporting cancer in 
numerous functions because by assisting in the maintenance of nuclear structures it plays a 
role in regulating gene expression and since cancer is a gene-regulated disease the 
possibilities are endless. Thus further studies may be carried out to discover these functions.  
It is clear that apoptosis is the mode of cell death in all three cell lines; however, the specific 
apoptotic pathway that is responsible for the reduction in cellular viability cannot be 
elucidated from these results hence further investigations can be carried. However, from 
literature the most common pathway observed in the caspase-3 deficient MCF-7 cells is the 
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death receptor pathway whereas for the MDA-MB 231 breast cancer cells it is the 
mitochondrial pathway and with WHCO1 oesophageal cancer cells both pathways are 
similarly favoured[152, 153]. This does not mean the same will be observed upon induction 
of cell death by downregulation of LRP/LR expression different apoptotic stimuli may 
activate either pathway, however this information and experimental investigation such as 
carrying out a caspase-8 and -9 assay can provide insight on the apoptotic pathway 
responsible in each cell line following knockdown of LRP/LR. 
 
 
4.6. LRP/LR as an alternative therapeutic tool for cancer treatment 
 
LRP/LR is a protein with multiple cellular localisations and functions, both physiological and 
pathological. It’s implications in cancer seem to be increasing, ranging from enhanced 
metastasis, invasion, cellular proliferation and cellular viability due to high expression in 
numerous cancers. The above mentioned processes are prominent hallmarks of cancer thus 
targeting of LRP/LR can be deemed a possible therapeutic tool for the treatment of cancers.  
Numerous in vitro studies targeting LRP/LR for the inhibition of these processes have been 
successful in various cancer cells using anti-LRP/LR specific antibodies, pentosan 
polysulfates, heparin mimetics to name a few. Moreover, a similar study investigating the 
effect of siRNA-mediated knockdown of LRP/LR on cellular viability of lung and cervical 
cancer cells has been carried out in our laboratory[110]. The expression levels of LRP/LR 
were significantly downregulated in both A549 lung and HeLa cervical cancer cells 
approximately 80% and 60%, respectively, when compared to non-transfected controls of 
these cell lines[110]. Furthermore, reduction in cellular viability of these cell lines was 
observed, however, the extent of LRP downregulation does not correlate to the extent of 
reduced cellular viability which is observed as well in the current study[110]. With regards to 
these two studies, the most significant reduction in LRP/LR expression was observed in 
MCF-7 breast and HeLa cervical cancer cells, however, this may vary amongst different cell 
lines thus one cannot speculate that similar results will be observed in other breast and 
cervical cancer cell lines[110]. Therefore, it is noteworthy to comprehend that not all cancers 
will be responsive to siRNA treatment and that the efficacy of this method will vary amongst 
different cancer types. Hence it is crucial to investigate how other cancers may respond to 
this method of treatment, thus provide insight on whether targeting of this receptor may be 
regarded an alternative broad spectrum therapeutic toll for the treatment of cancer. 
Therefore, LRP/LR directed tools can be utilised for the treatment of cancers that have been 
proven to be responsive to this mode of treatment, however, administration in the human 
body may pose difficult as this receptor is imperative for numerous physiological processes 
(cell differentiation, migration, adhesion and growth). Thus knockdown of LRP/LR may lead 
to inhibition of these crucial cellular processes causing deleterious homeostatic disruptions 
that could propagate the tumor further. Therefore target of solely cancer cells is crucial for 
use of anti-LRP/LR tools. 
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5. CHAPTER 5 – CONCLUSION AND FUTURE WORK 
 
5.1. Conclusion 
This study has illustrated that knockdown of LRP expression in breast MCF-7, MDA-MB 
231 and oesophageal WHCO1 cancer cells results in decreased cellular viability through the 
inhibition of cellular proliferation. The decrease in cell viability was observed to be due to the 
induction of apoptosis as indicated by the loss of nuclear morphology and exposure of the 
phosphatidylserine following membrane blebbing of MCF-7, MDA-MB 231 and WHCO1 
cells as shown by immunofluorescence microscopy and the Annexin-V FITC assay, 
respectively.  
Therefore these results strongly suggest the role of LRP/LR on the maintenance of cell 
viability of these cancers and targeting the mRNA of LRP with specific siRNA may 
potentially be used as an alternative therapeutic tool for the treatment of breast and 
oesophageal cancer cells. 
5.2. Future work 
The data shown addresses only two cancer types, namely breast and oesophageal cancer, 
therefore investigation of the effects of LRP downregulation on other prominent cancer types 
should be considered because various cancers behave differently, hence it cannot be assumed 
that this will hold true for all cancers. 
Additionally, research focusing on the effect of LRP downregulation on normal tissues could 
be carried out and if minimal effects are observed, investigations in animal models could be 
considered (i.e nude mice system). siRNAs could be administered via the tail vein of the mice 
following injection of cancerous cells into the mice. The progression of the cancer will be 
monitored for a certain period with specific analysis to the number as well as size of colonies 
as an indication of tumor progression.  
Furthermore, successful animal trials could pave way for clinical trials once appropriate 
delivery systems into the human body have been elucidated. A lentiviral or AAV delivery 
system may be utilised considering that LRP/LR binds numerous viruses i.e Sindbis, Dengue 
and AAV. Moreover, combination therapy of anti-LRP/LR specific antibodies and siRNAs 
could be appropriate for the targeting of metastasis, tumor angiogenesis and induction of 
apoptosis, respectively in these cancer cells. 
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7. CHAPTER 7 -  APPENDIX 
Determination of total LRP levels by Western blotting 
Lysis buffer 
Mix the following in dH2O: 
10 mM Tris-HCl  
100 mM NaCl  
10 mM EDTA  
0.5% (v/v) Nonident-P40  
0.05% (w/v) Deoxycholate  
Store solution at 4 °C 
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2X sample loading dye 
Mix the following in dH2O 
Sodium dodecyl sulphate polyacrlamide gel electrophoresis (SDS) 
1X SDS running buffer 
Mix the following in dH2O 
0.2 M Tris  
0.19 M Glycine  
3 mM SDS  
Store at room temperature (RT) 
 
40% acrylamide: Bis-Acrylamide 
Mix Acrylamide and Bis-Acrylamide (19:1) in dH2O 
Dissolve by heating, filter and store in dark bottle at 4
o
C 
 
Stacking buffer 
Mix the following in dH2O 
500 mM Tris  
pH to 6.8 with hydrochloric acid (HCl)  
Store at 4 °C 
 
Separation buffer 
Mix the following in dH2O 
1.5 M Tris  
pH to 8.8 with HCl  
Store at 4 °C 
 
10% SDS 
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Dissolve 10% (w/v) SDS in dH2O and store at RT 
 
1% APS 
Dissolve 1% (w/v) APS in dH2O and store at 4
o
C 
 
12% Separation and 5% Stacking gel were employed for the separation of the protein of 
interest, the 37kDa LRP 
12% Separation gel 
Mix the following in dH2O 
9.9% (v/v) 40% Acrylamide:Bis-Acrylamide  
25% (v/v) Separation buffer  
1% (v/v) 10% SDS  
1% (v/v) 1% APS  
0.4% (v/v) TEMED 
5% Stacking gel 
Mix the following in dH2O 
12.5% (v/v) 40% Acrylamide:Bis-Acrylamide  
12.5% (v/v) Stacking buffer  
1% (v/v) 10% SDS  
1% (v/v) 1% APS  
0.1% (v/v) TEMED 
 
Pouring gels 
Pour the 12% separation gel and overlay with ethanol until polymerised. Discard the ethanol, 
pour the 5% stacking gel and insert the comb immediately. 
Transfer buffer 
Mix the following in dH2O 
 20 mM Tris  
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150 mM Glycine  
20% Methanol  
Store at 4 °C 
 
Blocking buffer 
3% BSA-PBS-Tween 
Dissolve 3% BSA in PBS Tween 
Store at 4
o
C 
 
1X PBS 
 Mix the following in dH20:  
137 mM NaCl  
12 mM Phosphate  
2.7 mM KCl  
pH 7.4  
Store at RT 
 
PBS-Tween 
Add 0.001% Tween to 1 X PBS  
Store at 4 °C 
Transfection per well (24 well plate) 
MCF-7, MDA-Mb 231 and WHCO1 cells were seeded in the wells of a 24 well plate. 24 h 
later,  1.25 μl of 10 μM siRNA-LAMR1/ siRNA-scr and 2.5 µL of DharmaFECT® 1 
transfection reagent were each concurrently diluted in serum-free DMEM to a final volume 
of 50 µL each, the contents of each tube was gently mixed and allowed to incubate for 5 min 
at RT. The diluted siRNA-LAMR1 solution was then added to the diluted DharmaFECT® 1 
transfection reagent, mixed gently and incubated for 20 min at RT. The culture medium was 
removed from the plated cells and 400 µL DMEM containing 10% (v/v) FCS added to the 
siRNA-reagent solution which the cells were then grown in for 72 h in a humidified incubator 
at 37 °C with 95% air and 5% CO2.  
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8mM PCA 
Dissolve 8mM PCA in DMEM supplemented with 10% FCS (v/v) and store in at 4
o
C. 
 
